News Madrigal Pharmaceuticals Presents Late-Breaking Phase 3 NASH Data and Multiple Oral Abstracts at EASL’s International Liver Congress™ Continue Reading Previous Vir Biotechnology Announces New Clinical Data From its Broad Hepatitis B ProgramNext Pfizer and BioNTech Announce Omicron-Adapted COVID-19 Vaccine Candidates Demonstrate High Immune Response Against Omicron Related Stories News FLYR Expands Two-Year Presence and Major Investment in Saudi Arabia with Regional Headquarters News OnStation and Trimble: Live Digital Stationing Meets Location Precision News Fireflies launches Live Assist and Desktop App to deliver real-time help in every meeting News Aurasell Ends Tool Sprawl With Rapid Growth of the First AI-Native GTM Platform News SkySafe Unveils Forensics as a Service, Completing the Industry’s First End-to-End Drone Detection and Airspace Intelligence Platform News isolved Elevates the Customer Experience Through Innovation, Connection and Care
